Loading…
A Phase I Study of a New Nucleoside Analogue, OSI-7836, Using Two Administration Schedules in Patients with Advanced Solid Malignancies
Purpose: To investigate the safety, tolerability, and pharmacokinetic profile of the novel nucleoside analogue OSI-7836 in patients with advanced solid malignancies. Experimental Design: OSI-7836 was initially given as a 60-minute i.v. infusion on day 1 every 21 days. In view of its dose-limiting to...
Saved in:
Published in: | Clinical cancer research 2006-05, Vol.12 (9), p.2841-2848 |
---|---|
Main Authors: | , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Purpose: To investigate the safety, tolerability, and pharmacokinetic profile of the novel nucleoside analogue OSI-7836 in patients
with advanced solid malignancies.
Experimental Design: OSI-7836 was initially given as a 60-minute i.v. infusion on day 1 every 21 days. In view of its dose-limiting toxicities,
the administration time was amended to a 5-minute bolus, and subsequently, the schedule was amended to weekly for 4 weeks
followed by a 2-week rest. Blood and urine samples were collected for pharmacokinetic studies. Analyses of cytokines and lymphocyte
subsets were added later in the study to elucidate a mechanism for the severe fatigue and lymphocyte depletion observed in
earlier patients.
Results: Thirty patients received a total of 61 treatment cycles. Fatigue was the main dose-limiting toxicity. Maximum-tolerated dose
was defined as 300 mg/m 2 in the 60-minute infusion, (three times per week) schedule; 400 mg/m 2 in the 5-minute bolus infusion, (three times per week) schedule; and 100 mg/m 2 in the weekly schedule. Other common toxicities were nausea, vomiting, rash, fever, and a flu-like syndrome. There were no
clinically significant hematologic toxicities. Following the initial dose, OSI-7836 was eliminated from plasma with a median
(range) elimination half-life of 48.3 minutes (22.6-64.8 minutes). Lymphocyte subset analysis showed a significant drop in
B cell counts, which persisted to day 14 and beyond. Cytokine analysis showed significant elevations of interleukin-6 and
interleukin-10 in all patients who received ≥200 mg/m 2 OSI-7836. Best response was disease stabilization in seven patients.
Conclusion: OSI-7836 was associated with excessive fatigue, and despite changes in its schedule and duration of administration, we did
not observe an improvement in its tolerability. Its potentially selective effect on B lymphocytes could be exploited in further
studies in specific hematologic malignancies. |
---|---|
ISSN: | 1078-0432 1557-3265 |
DOI: | 10.1158/1078-0432.CCR-05-1932 |